PLSE news

Pulse Biosciences announced a commercial and clinical partnership with the Clayman Thyroid Center to treat benign thyroid nodules, advancing market development for its nanosecond pulsed field ablation technology.

Pulse Biosciences enrolled 164 patients in its pivotal NANOPULSE-AF study ahead of schedule, demonstrating strong investigator interest in its cardiac catheter system.

Pulse Biosciences announced the enrollment of 100 patients across three U.S. sites in the PRECISE-BTN clinical study evaluating its nPulse Percutaneous Electrode System, with first patient visitation marking milestone progress in the development of novel bioelectric medicine for thyroid nodules.

Pulse Biosciences reports enrollment is ahead of schedule in its NANOPULSE-AF pivotal study, driven by investigator enthusiasm and an intuitive workflow. This could positively impact the company's chances of regulatory approval.

Pulse Biosciences intends to redeem its remaining common stock warrants issued in July 2024, with an exercise deadline of July 13, 2026 at $11.00 per share or redemption at $0.01 per warrant. The company has already raised $123.7 million from its rights offering and warrant redemptions, demonstratin…